• This record comes from PubMed

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

. 2017 Jul 01 ; 28 (suppl_4) : iv52-iv61.

Language English Country Great Britain, England Media print

Document type Journal Article, Practice Guideline

Links

PubMed 28453614
DOI 10.1093/annonc/mdx096
PII: S0923-7534(19)42145-5
Knihovny.cz E-resources

References provided by Crossref.org

Newest 20 citations...

See more in
Medvik | PubMed

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

. 2021 Jun 02 ; 21 (1) : 659. [epub] 20210602

Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up

. 2021 Feb ; 5 (2) : e528. [epub] 20210203

Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma

. 2020 Sep 27 ; 9 (10) : . [epub] 20200927

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials

. 2020 Apr ; 105 (4) : 1074-1080. [epub] 20190627

Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting

. 2019 Dec ; 7 (2) : 141-157. [epub] 20191103

Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma

. 2019 Nov ; 187 (4) : 447-458. [epub] 20190806

Insights on Multiple Myeloma Treatment Strategies

. 2019 Feb ; 3 (1) : e163. [epub] 20181227

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma

. 2018 ; 9 () : 2431. [epub] 20181116

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

. 2018 Sep ; 103 (9) : 1518-1526. [epub] 20180628

Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

. 2018 Mar ; 103 (3) : 514-521. [epub] 20171207

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

. 2018 Feb ; 103 (2) : 197-211. [epub] 20171207

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...